Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9968760 | 0.86 | L3MBTL1 (0.41) | HDAC1HDAC8AAK1TBXA2R | |
| SCHEMBL6895839 | 0.83 | CNR2 (0.36) | HDAC1HDAC8AAK1ACACB | |
| SCHEMBL421355 | 0.82 | GNRHR (0.48) | HDAC1HDAC8 | |
| SCHEMBL10298786 | 0.78 | HDAC1 (0.54) | HDAC1HDAC8 | |
| SCHEMBL418842 | 0.76 | ALDH1A1 (0.43) | — | |
| SCHEMBL12636229 | 0.75 | HDAC6 (0.45) | HDAC1AAK1TBXA2R | |
| SCHEMBL10176988 | 0.74 | GNRHR (0.48) | HDAC1 | |
| SCHEMBL9931288 | 0.73 | GNRHR (0.41) | AAK1TBXA2R | |
| SCHEMBL9931306 | 0.73 | KDM4E (0.46) | HDAC1HDAC8TBXA2R | |
| SCHEMBL6896313 | 0.72 | GNRHR (0.47) | HDAC1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172350-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2011-03-17 | — | — | US | disclosed |
| WO-2011031816-A2 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031818-A2 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | HRH3, HRH4, HRH2 | HDAC1 791/4885HDAC8 703/4885AAK1 1164/4885 |
| US-20120172350-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | HDAC1 791/4885HDAC8 703/4885AAK1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.